Skyline Biotech IPO: Related-Party Lease, Discounted CFO Sale and a Connected Allocation
Skyline Biotech Limited is a Cayman-incorporated, Hong Kong-based pre-revenue biotech company seeking a Main Board IPO under Chapter 18A. Its lead drug is in Phase II trials; pre-money valuation is HKD 900 million. Orion Capital, a Type 6 licensed sponsor, is conducting due diligence. Orion finds that Skyline's lab lease (HKD 1.2 million per year) is with a company 30% owned by the founder's spouse and is not mentioned in the draft prospectus. Three months before the filing, Skyline's CFO sold 2% of the company to an offshore fund at a 40% discount to the proposed IPO price. A top-five supplier holds 10% of Skyline. The bookrunner wants to allocate 15% of the offer to a private-banking client who is also a director of the supplier. The target offer size is HKD 600 million.
1. What should Orion do about the lease and the CFO share sale before the filing?
Read the worked answer
Orion must conduct reasonable due diligence under paragraph 17 of the SFC Code of Conduct and ensure the prospectus is accurate and not misleading. The lease is a related-party transaction. Under HKEX Listing Rules Chapter 14A, a connected transaction at or before listing may require disclosure in the prospectus and, if material or continuing, independent shareholder approval. The founder's spouse's 30% interest makes the landlord a connected person. Orion should obtain the lease, valuation, market comparables, board minutes and independent legal advice; if the rent is above market or the lease is not on normal commercial terms, it must be disclosed and possibly terminated or approved. The CFO's 2% sale at a 40% discount is a pre-IPO investment that raises valuation and disclosure questions: the prospectus should disclose the sale, the price, the identity of the fund and any relationship with the company. Orion should assess whether the discount reflects a genuine valuation or a benefit; if the fund is a connected person, Chapter 14A applies. Orion should escalate to its investment banking committee and, if unsatisfied, decline to sponsor.
2. Can the bookrunner allocate 15% to the private-banking client? Explain the Listing Rules and Code of Conduct issues.
Read the worked answer
The allocation is not prohibited outright, but it is a conflict. The client is a director of a 10% shareholder, so he may be a connected person of the issuer. Under Chapter 14A, a connected transaction requires disclosure and independent shareholder approval unless an exemption applies. An allocation of IPO shares to a connected person may be a transaction with a connected person; the issuer should disclose it and obtain approval. If the client is only connected to the bookrunner, the bookrunner must apply its allocation policy, avoid preferential treatment, disclose the connection to the issuer, and ensure the allocation is not conditional on unrelated business. The SFC expects bookrunners to maintain allocation records and to manage conflicts. The sponsor should require the issuer's board to approve and disclose the allocation, and should consider whether 15% is fair given demand.
3. If the CFO sale is discovered after the prospectus is published, what are the sponsor's options?
Read the worked answer
Orion must immediately notify the SFC and HKEX, suspend the offering, and assess whether the prospectus contains a material misstatement or omission. Options include issuing a supplemental prospectus, withdrawing and re-launching the offer, or terminating the sponsor engagement if the issuer is not cooperative. Orion should conduct an internal investigation, preserve records, and consider its obligations under paragraph 17 of the Code of Conduct. It should not rely on the CFO's explanation alone. If the omission is material, the sponsor may face liability, and the SFC may take disciplinary action. The issuer should also consider making an announcement and obtaining independent legal advice. Timing matters: the sponsor must act before investors subscribe on a defective prospectus.